CA2208149A1 - Sustained release caffeine formulation - Google Patents

Sustained release caffeine formulation

Info

Publication number
CA2208149A1
CA2208149A1 CA002208149A CA2208149A CA2208149A1 CA 2208149 A1 CA2208149 A1 CA 2208149A1 CA 002208149 A CA002208149 A CA 002208149A CA 2208149 A CA2208149 A CA 2208149A CA 2208149 A1 CA2208149 A1 CA 2208149A1
Authority
CA
Canada
Prior art keywords
stimulant
composition
sustained release
solid particles
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002208149A
Other languages
French (fr)
Other versions
CA2208149C (en
Inventor
Francoise Chauffard
Marc Y. A. Enslen
Pierre Tachon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe Des Produits Nestle S.A.
Francoise Chauffard
Marc Y. A. Enslen
Pierre Tachon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe Des Produits Nestle S.A., Francoise Chauffard, Marc Y. A. Enslen, Pierre Tachon filed Critical Societe Des Produits Nestle S.A.
Publication of CA2208149A1 publication Critical patent/CA2208149A1/en
Application granted granted Critical
Publication of CA2208149C publication Critical patent/CA2208149C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

The present invention relates to a composition for the controlled release of a stimulant of xanthine or a xanthine derivative, which comprises microparticles including a biodegradable matrix of at least one water-soluble material and the stimulant, said stimulant being in the form of solid particles which are substantially uniformly distributed throughout the matrix. It is also concerning a method for making this composition by dispersing the stimulant in the form of a plurality of solid particles into a biodegradable matrix. Such composition can advantageously be orally administrated for increasing the alertness of an individual.
CA002208149A 1994-12-16 1995-11-27 Sustained release caffeine formulation Expired - Lifetime CA2208149C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/357,689 1994-12-16
US08/357,689 US5744164A (en) 1994-12-16 1994-12-16 Sustained release microparticulate caffeine formulation
PCT/IB1995/001056 WO1996018389A1 (en) 1994-12-16 1995-11-27 Sustained release caffeine formulation

Publications (2)

Publication Number Publication Date
CA2208149A1 true CA2208149A1 (en) 1996-06-20
CA2208149C CA2208149C (en) 2007-03-27

Family

ID=23406640

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208149A Expired - Lifetime CA2208149C (en) 1994-12-16 1995-11-27 Sustained release caffeine formulation

Country Status (21)

Country Link
US (2) US5744164A (en)
EP (2) EP0716853A1 (en)
JP (1) JPH10510529A (en)
AR (1) AR002947A1 (en)
AT (1) ATE201986T1 (en)
AU (1) AU694810B2 (en)
CA (1) CA2208149C (en)
CO (1) CO4600671A1 (en)
DE (1) DE69521328T2 (en)
DK (1) DK0789562T3 (en)
ES (1) ES2158956T3 (en)
GR (1) GR3036501T3 (en)
HK (1) HK1000878A1 (en)
IL (1) IL116066A (en)
NZ (1) NZ295245A (en)
PE (1) PE55396A1 (en)
PT (1) PT789562E (en)
RU (1) RU2144353C1 (en)
TR (1) TR199501560A2 (en)
WO (1) WO1996018389A1 (en)
ZA (1) ZA9510687B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833617A1 (en) * 1995-06-20 1998-04-08 Pharma-Vinci A/S A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US6491540B1 (en) * 1999-09-20 2002-12-10 Jack Barreca Center-filled supplement gum
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US7897141B2 (en) * 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US20030220351A1 (en) * 2002-05-24 2003-11-27 Gilbert Gonzales Enteric coated caffeine tablet
AU2003292110A1 (en) * 2002-11-25 2004-06-18 Phares Pharmaceutical Research N.V. Confectionery composition
US20050181044A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
US20050220875A1 (en) * 2004-03-31 2005-10-06 Agency For Science, Technology And Research Sustained-release tablet formulation
FR2883179B1 (en) 2005-03-18 2009-04-17 Ethypharm Sa COATED TABLET
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
RU2571067C2 (en) * 2009-01-22 2015-12-20 Эбботт Хелткеа Прайвит Лимитед Chronotherapeutic pharmaceutical composition
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
US8992898B2 (en) 2010-04-17 2015-03-31 Shannon Elizabeth Klingman Antiperspirants and deodorants
US20160128943A1 (en) * 2013-06-04 2016-05-12 KVK-Tech, Inc. Controlled release caffeine dosage forms
CA2978593A1 (en) 2015-01-12 2016-07-21 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
KR101644154B1 (en) * 2015-09-08 2016-07-29 주식회사 스킨앤테크 Water soluble caffeine, preparing method thereof using the same
US10582716B1 (en) 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
US20220288083A1 (en) * 2021-03-09 2022-09-15 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof
CN117750947A (en) * 2021-07-30 2024-03-22 宝龄富锦生技股份有限公司 Controlled release oral formulation and method of preparing the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265629A (en) * 1958-12-22 1966-08-09 Ncr Co Coating by phase separation
DE1249219B (en) * 1958-12-22 1967-09-07 The National Cash Register Company, Dayton, Ohio (V. St. A.) Manufacture of microcapsules that contain an emulsion of oil in hydrophilic liquid
DE2010416B2 (en) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Orally applicable dosage form with sustained release effect
US4001480A (en) * 1974-08-16 1977-01-04 Swift & Company Encapsulation process utilizing microorganisms and products produced thereby
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
NZ207813A (en) * 1983-06-24 1986-12-05 Dridrinks Nv Effervescent mixture:component(s)coated with water-soluble polysaccharide composition
DE3474099D1 (en) * 1983-06-24 1988-10-27 Dridrinks Nv Treatment of acids as compounds of water-soluble, powdery compositions intended for preparing beverages with lasting gaseous delivery.
NZ210785A (en) * 1984-01-13 1987-11-27 Battelle Development Corp Liquid dispersions of layered controlled release dosage forms
DE3403329A1 (en) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe PHARMACEUTICAL PRODUCT IN THE FORM OF PELLETS WITH CONTINUOUS, DELAYED DELIVERY OF ACTIVE SUBSTANCES
DK62184D0 (en) * 1984-02-10 1984-02-10 Benzon As Alfred DIFFUSION COATED POLYDEPOT PREPARATION
DE3586600T2 (en) * 1984-02-10 1993-02-18 Benzon Pharma As DOSAGE CONTAINING A VARIETY WITH A DIFFERENTIAL COVERED UNITS.
NL8500724A (en) * 1985-03-13 1986-10-01 Univ Groningen DEVICES FOR REGULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD OF MANUFACTURE THEREOF
DE3537770A1 (en) * 1985-10-24 1987-04-30 Basf Ag SALTS OF MULTIPLE VALUE CATIONS OF POLYMERISATS FROM CONJUGATED SERVES
US4853249A (en) * 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US5026709A (en) * 1986-04-07 1991-06-25 Rorer Pharmaceutical Corporation Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
AU7280387A (en) * 1986-04-07 1987-11-09 Rorer International (Overseas) Inc. Method for the preparation of a sustained release pharmaceutical composition and the compostion prepared thereby
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
JP2643222B2 (en) * 1988-02-03 1997-08-20 エーザイ株式会社 Multi-layer granules
US4971785A (en) * 1988-03-14 1990-11-20 Spectrum Consumer Products Co., Inc. Non-alcoholic delivery system for orally ingestible active ingredients
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JPH06316517A (en) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd Sustained-release preparation

Also Published As

Publication number Publication date
AR002947A1 (en) 1998-05-27
HK1000878A1 (en) 2001-10-26
ATE201986T1 (en) 2001-06-15
WO1996018389A1 (en) 1996-06-20
US5744164A (en) 1998-04-28
ZA9510687B (en) 1996-07-03
IL116066A0 (en) 1996-01-31
DK0789562T3 (en) 2001-09-03
DE69521328T2 (en) 2002-01-17
US5700484A (en) 1997-12-23
NZ295245A (en) 1999-01-28
GR3036501T3 (en) 2001-11-30
IL116066A (en) 2000-10-31
CO4600671A1 (en) 1998-05-08
PT789562E (en) 2001-10-30
RU2144353C1 (en) 2000-01-20
JPH10510529A (en) 1998-10-13
EP0789562B1 (en) 2001-06-13
AU694810B2 (en) 1998-07-30
ES2158956T3 (en) 2001-09-16
PE55396A1 (en) 1996-12-24
AU3854295A (en) 1996-07-03
EP0716853A1 (en) 1996-06-19
DE69521328D1 (en) 2001-07-19
CA2208149C (en) 2007-03-27
TR199501560A2 (en) 1996-07-21
EP0789562A1 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
CA2208149A1 (en) Sustained release caffeine formulation
CA2328703A1 (en) Delavirdine tablet formulation
NZ333844A (en) Compositions comprising mircoparticles of water-insoluble substances and method for preparing same
CA2270975A1 (en) Stabilized sustained release tramadol formulations
EP0776660A3 (en) Long-lasting release nifedipine preparation
MX9603480A (en) Process for preparing fine particle pharmaceutical formulations.
CA2029046A1 (en) Sustained release compositions for treating periodontal disease
FR2776520B1 (en) NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PEPTIDES AND THEIR PREPARATION PROCESS
CA2106774A1 (en) Method for the preparation of feed pellets
HUP0000383A3 (en) Tetrahydrochinoxalinyl-aminoalkane phosphonic acids, process for their preparation and pharmaceutical compositions thereof
AU574024B2 (en) Polycaprolactone matrix for oral drug administration
HUP0100303A2 (en) Porous hydroxyapatite particles as carriers for drug substances
GB0008411D0 (en) Pharmaceutical preparations and their manufacture
CA2374418A1 (en) Process for making a pipa-polyol
AU3299293A (en) New pyrethrinoid esters derived from thiazolic alcohols, their preparation process and their use as pesticides
AU2366088A (en) 2,2-dimethylchromene derivatives, process for their preparation and pharmaceutical compositions in which they are present
IE801901L (en) Controlled release parasitic formulations
CA2324254A1 (en) Sustained-release composition including amorphous polymer
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
CA2212242A1 (en) Stable arylpyrrole particles, process for their preparation and suspension concentrate compositions comprising them
HUT53636A (en) Insecticide and acaricide comprising n-amino-1,2,4-triazine derivative as active ingredient and process for producing the active ingredient
AU1833888A (en) 2,2-dimethylchroman-3-ol derivatives, process for their preparation and pharmaceutical compositions in which they are present
CA2360649A1 (en) Method of preparing particles for agglomeration
ZA924967B (en) Pyrethrinoid esters of 4-amino 2,3,5,6-tetrafluorophenyl methyl alcohol, their preparation process and their use as pesticides.
AU4458696A (en) 1,2,4-triazine derivatives, process for producing the same, and herbicide comprising the same as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151127